The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 |
|---|---|---|
| Net income (loss) | -1,799,404 | 2,819,021 |
| Depreciation and amortization | 11,183 | 41,522 |
| Loss on extinguishment of debt | 0 | -6,329,593 |
| Change in value of contingent consideration | 140,000 | 370,000 |
| Change in value of equity securities | 0 | 156,849 |
| Stock-based compensation expense | 128,819 | 181,312 |
| Restricted shares for services rendered | 268,680 | - |
| Gain on bankruptcy of subsidiary | 0 | 12,019,227 |
| Long-lived asset impairment | 0 | 831,915 |
| Gain on settlement of accounts payable | 0 | 22,324 |
| Amortization of debt issuance cost | - | 18,495 |
| Amortization of discount of notes payable | 58,495 | - |
| Other receivables | 1,750 | 6,407 |
| Prepaid expenses/deposits | -152,708 | -269,264 |
| Accounts payable | 245,191 | 532,206 |
| Accrued expenses | 88,541 | 205,738 |
| Other current liabilities | 2,917 | 0 |
| Operating leases, net | -68,098 | -3,369 |
| Net cash used in operating activities | -1,071,213 | -1,349,110 |
| Sale of equitable securities | 0 | 544,700 |
| Purchase of property and equipment | 1,238 | - |
| Net cash provided by investing activities | -1,238 | 544,700 |
| Repayment of finance agreement | 0 | 271,643 |
| Proceeds from private placement | 750,000 | - |
| Proceeds from notes payable | 200,000 | 1,615,000 |
| Net cash provided by financing activities | 950,000 | 1,343,357 |
| Effect of exchange rates on cash | -10,712 | -6,839 |
| Net change in cash | -133,163 | 532,108 |
| Cash and cash equivalents at beginning of period | 624,808 | 92,700 |
| Cash and cash equivalents at end of period | 491,645 | 624,808 |
Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. (LNAI)